Myriad Genetics (MYGN)
(Delayed Data from NSDQ)
$26.55 USD
-0.38 (-1.41%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $26.56 +0.01 (0.04%) 7:14 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$26.55 USD
-0.38 (-1.41%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $26.56 +0.01 (0.04%) 7:14 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Zacks News
Here's Why Myriad Genetics (MYGN) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Should You Continue to Retain MYGN Stock in Your Portfolio?
by Zacks Equity Research
Myriad Genetics is advancing with strategic priorities, and bringing new products and upgrades to the market, positively influencing investors' sentiment.
Myriad (MYGN) Down 4.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Partnerships to Aid Myriad Genetics Stock Amid Macro Issues
by Zacks Equity Research
MYGN focuses on effective capital deployment in key areas, including new tech-enabled tools and capabilities, innovation and commercial capabilities.
Why Myriad Genetics (MYGN) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Alcon's (ALC) Market Share Gains, New Launches Aid Growth
by Zacks Equity Research
Alcon (ALC) is witnessing growth in its over-the-counter portfolio, driven by favorable pricing and a sustained family of products.
Should You Hold Hologic (HOLX) Stock in Your Portfolio Now?
by Zacks Equity Research
Hologic's (HOLX) strength in molecular diagnostics and the enriched Breast Health business are encouraging.
Walgreens (WBA) Partners With BARDA to Boost Clinical Research
by Zacks Equity Research
Walgreens (WBA) and BARDA form a strategic partnership to bolster the decentralized clinical trial model.
Quest Diagnostics (DGX) Debuts Micronutrient Deficiency Panels
by Zacks Equity Research
Quest Diagnostics (DGX) introduces 13 blood tests to identify micronutrient deficiencies.
Should You Hold Edward Lifesciences (EW) in Your Portfolio Now?
by Zacks Equity Research
Edward Lifesciences' (EW) promising TAVR business and the Critical Care divestment move bode well in the long term.
Why You Should Add Exact Sciences (EXAS) to Your Portfolio
by Zacks Equity Research
Exact Sciences' (EXAS) progress with strategic priority and strong solvency bode well.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Should Quest Diagnostics (DGX) be in Your Portfolio Now?
by Zacks Equity Research
Quest Diagnostics' (DGX) robust base business performance instills optimism for long-term growth.
Myriad Genetics (MYGN) Q2 Earnings Surpass, '24 Outlook Raised
by Zacks Equity Research
Myriad Genetics (MYGN) delivers a strong performance across its portfolio in the second quarter of 2024 and increases its long-term revenue growth rate target.
Myriad (MYGN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Myriad (MYGN) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Myriad Genetics (MYGN) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Myriad (MYGN) delivered earnings and revenue surprises of 600% and 2.91%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Moderna (MRNA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Moderna (MRNA) delivered earnings and revenue surprises of 4.03% and 92.92%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
INCY or MYGN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
INCY vs. MYGN: Which Stock Is the Better Value Option?
Myriad Genetics (MYGN) Expands in MRD Testing With New Collab
by Zacks Equity Research
Myriad Genetics (MYGN) inks an agreement with Personalis to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease. The idea is to broaden patient access to the benefits of MRD testing.
Myriad Genetics (MYGN) Advances in MRD Space With New Patent
by Zacks Equity Research
Myriad Genetics (MYGN) achieves a second foundational patent bolstering the MRD assay development.
Myriad Genetics (MYGN) and GSK Unite to Boost HRD Testing
by Zacks Equity Research
Myriad Genetics (MYGN) collaborates with GSK to improve access to HRD diagnostic testing for HGSOC patients.
Myriad Genetics (MYGN) Banks on Innovation Amid Macro Woes
by Zacks Equity Research
Myriad Genetics (MYGN) continues to enhance its customer targeting, digital marketing and overall operating model to drive commercial leverage in 2024 and beyond.
Myriad (MYGN) Down 5.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
QIAGEN (QGEN) Develops Test for Research and CDx Application
by Zacks Equity Research
QIAGEN's (QGEN) next-generation sequencing test aims to aid personalized medicine research in solid tumor types, including ovarian cancer, and improve decentralized testing capabilities.
Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Loss in Q1
by Zacks Equity Research
Myriad Genetics (MYGN) first-quarter average revenue per test across its product portfolio benefited from expanded coverage and ongoing efforts in revenue cycle management.